Adel Schwertani is corecipient of the sixth Tomoh Masaki Award
RI-MUHC scientist receives international acclaim for research that benefits pulmonary arterial hypertension patients
RI-MUHC study shows impact of combinatorial immunotherapy on an aggressive cancer
A combinatorial immunotherapy may provide significant therapeutic benefit in managing pancreatic ductal...
RI-MUHC team studies a novel, fully automated insulin delivery system
A new publication in Lancet Digital Health describes an important step that may improve glucose control and quality of life for people with type 1...
RI-MUHC team detects impact of HIV antiretroviral therapy on the anti-tuberculosis immune response
Alveolar macrophages, cells important for protection from tuberculosis infection, are adversely impacted by...
Discovery of mechanics of drug targets for COVID-19
Scientists unravel inner workings of cell receptors involved in inflammatory diseases
RI-MUHC researchers tackle COVID-19 vaccine hesitancy in adults and in children
Videos from projects led by Drs. Inés Colmegna and Moshe Ben-Shoshan are now available
RI-MUHC scientist part of McGill team delivering World Alzheimer Report 2021
Alzheimer’s Disease International webinar launches report on World Alzheimer Day, September 21
Research trainees are bridging the gap between science and the public
Two RI-MUHC research trainees share their experience as community outreach panelists
Promising development in the fight with cancer using artificial intelligence
New privacy-preserving approach uses hospital based medical notes to refine predictions and prognosis in cancer...
New G protein inhibitor identified, with potential for cancer therapies
RI-MUHC team publishes study in Nature Communications describing a novel molecule that inhibits growth of cancer cells